National Cancer Institute; Notice of Closed Meetings, 21640 [2010-9636]

Download as PDF sroberts on DSKD5P82C1PROD with NOTICES 21640 Federal Register / Vol. 75, No. 79 / Monday, April 26, 2010 / Notices current Haemophilus influenzae type b conjugate vaccines have no protective effect against nontypeable strains. The technologies described herein are conjugate vaccines against nontypeable Haemophilus influenzae. The vaccines are comprised of lipooligosaccharides (LOS) from which esterified fatty acids have been removed from lipid A to form detoxified LOS conjugated to an immunogenic carrier such as tetanus toxoid, and an adjuvant such as alum. In vivo data in the Chinchilla animal model are available. The vaccines can be potentially used as a component in a combination vaccine with other pediatric vaccine components. Applications: Vaccines for the prevention of respiratory infections and otitis media caused by nontypeable Haemophilus influenzae. Advantages: • Novel vaccine candidates. • Conserved antigen. Development Status: In vitro and in vivo data can be provided upon request. Data is also available from a phase I clinical trial with a representative vaccine showing safety and immunogenicity in adults. Market: • Pediatric vaccines. • Preventative vaccines. Inventors: Xin-xing Gu (NIDCD), John Robbins (NICHD), et al. Related Publication: W Hong et al. Protection against nontypeable Haemophilus influenzae challenges by mucosal vaccination with a detoxified lipooligosaccharide conjugate in two chinchilla models. Microbes Infect. 2010 Jan;12(1):11–18. [PubMed: 19782149] Patent Status: • U.S. Patent 6,207,157 issued 27 Mar 2001 (HHS Ref. No. E–228–1995/1–US– 01). • U.S. Patent 6,607,725 issued 19 Aug 2003 (HHS Ref. No. E–228–1995/1–US– 02). • U.S. Patent 7,641,906 issued 05 Jan 2010 (HHS Ref. No. E–217–2001/0–US– 06). Licensing Status: Available for licensing. Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; changke@mail.nih.gov. Collaborative Research Opportunity: The National Institute on Deafness and Other Communication Disorders, Vaccine Research Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the subject technology. Please contact Brian W. Bailey, Ph.D. at 301–594–4094 or bbailey@mail.nih.gov for more information. VerDate Nov<24>2008 16:56 Apr 23, 2010 Jkt 220001 Dated: April 20, 2010. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2010–9641 Filed 4–23–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, T32 Review. Date: May 11, 2010. Time: 5 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Crystal City, 2399 Jefferson Davis Hwy, Arlington, VA 22202. Contact Person: Robert Bird, PhD, Chief, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8113, Bethesda, MD 20892–8328, 301– 496–7978, birdr@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Epidemiology, Prevention, Control and Population Sciences. Date: May 26–27, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington DC/Rockville, Rockville, MD 20852. Contact Person: Wlodek Lopaczynski, M.D., PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8131, Bethesda, MD 20892, 301–594–1402, lopacw@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Cellular & Tissue Biology P01. Date: May 26–28, 2010. Time: 5 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Shakeel Ahmad, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8139, Bethesda, MD 20892–8328, (301) 594–0114, ahmads@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, State and Community Tobacco Control Policy and Media Research. Date: May 26–27, 2010. Time: 7 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Legacy Hotel and Conference Center, 1775 Rockville Pike, Rockville, MD 20852. Contact Person: Gerald G. Lovinger, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8101, Bethesda, MD 20892–8329, 301/496–7987, lovingeg@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 20, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–9636 Filed 4–23–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. E:\FR\FM\26APN1.SGM 26APN1

Agencies

[Federal Register Volume 75, Number 79 (Monday, April 26, 2010)]
[Notices]
[Page 21640]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9636]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, T32 Review.
    Date: May 11, 2010.
    Time: 5 p.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Crystal City, 2399 Jefferson Davis Hwy, Arlington, 
VA 22202.
    Contact Person: Robert Bird, PhD, Chief, Resources and Training 
Review Branch, Division of Extramural Activities, National Cancer 
Institute, 6116 Executive Boulevard, Room 8113, Bethesda, MD 20892-
8328, 301-496-7978, birdr@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Epidemiology, Prevention, Control and Population Sciences.
    Date: May 26-27, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Washington DC/Rockville, Rockville, MD 20852.
    Contact Person: Wlodek Lopaczynski, M.D., PhD, Scientific Review 
Officer, Research Programs Review Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Blvd., Room 
8131, Bethesda, MD 20892, 301-594-1402, lopacw@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Cellular & Tissue Biology P01.
    Date: May 26-28, 2010.
    Time: 5 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Shakeel Ahmad, PhD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8139, 
Bethesda, MD 20892-8328, (301) 594-0114, ahmads@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, State and Community Tobacco Control Policy and Media 
Research.
    Date: May 26-27, 2010.
    Time: 7 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Legacy Hotel and Conference Center, 1775 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Gerald G. Lovinger, PhD, Scientific Review 
Officer, Special Review and Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Blvd., Room 
8101, Bethesda, MD 20892-8329, 301/496-7987, lovingeg@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: April 20, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-9636 Filed 4-23-10; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.